[Br:1][CH2:2][C:3]([O:5][C:6]([CH3:9])([CH3:8])[CH3:7])=[O:4].[C:10]([O:14][C:15]([NH:17][CH:18]([C:30]1[CH:35]=[CH:34][CH:33]=[CH:32][CH:31]=1)[C:19]([O:21][C@@H:22]1[CH:27]2[CH2:28][CH2:29][N:24]([CH2:25][CH2:26]2)[CH2:23]1)=[O:20])=[O:16])([CH3:13])([CH3:12])[CH3:11]>C(#N)C>[Br-:1].[C:6]([O:5][C:3](=[O:4])[CH2:2][N+:24]12[CH2:25][CH2:26][CH:27]([CH2:28][CH2:29]1)[C@@H:22]([O:21][C:19](=[O:20])[CH:18]([NH:17][C:15]([O:14][C:10]([CH3:12])([CH3:11])[CH3:13])=[O:16])[C:30]1[CH:35]=[CH:34][CH:33]=[CH:32][CH:31]=1)[CH2:23]2)([CH3:9])([CH3:8])[CH3:7]Tert-butyl 2-bromoacetate (29.5 μl, 0.20 mmol) was added to a solution of (R)-quinuclidin-3-yl 2-(tert-butoxycarbonylamino)-2-phenylacetate (C1) (72 mg, 0.20 mmol) in acetonitrile (3 ml). The reaction was stirred at RT overnight. The product was collected by suction filtration and then purified by flash chromatography (DCM/MeOH=98/2 to 95/5) to get (3R)-1-(2-tert-butoxy-2-oxoethyl)-3-(2-(tert-butoxycarbonylamino)-2-phenylacetoxy)-1-azoniabicyclo[2.2.2]octane bromide (97 mg; 87% yield).